Institution
University of British Columbia
Education•Vancouver, British Columbia, Canada•
About: University of British Columbia is a education organization based out in Vancouver, British Columbia, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 89939 authors who have published 209679 publications receiving 9226862 citations. The organization is also known as: UBC & The University of British Columbia.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Cryopreservable human NSCs may be propagated by both epigenetic and genetic means that are comparably safe and effective, and may allow the development of NSC transplantation for a range of disorders.
Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. These self-renewing clones give rise to all fundamental neural lineages in vitro. Following transplantation into germinal zones of the newborn mouse brain they participate in aspects of normal development, including migration along established migratory pathways to disseminated central nervous system regions, differentiation into multiple developmentally and regionally appropriate cell types, and nondisruptive interspersion with host progenitors and their progeny. These human NSCs can be genetically engineered and are capable of expressing foreign transgenes in vivo. Supporting their gene therapy potential, secretory products from NSCs can correct a prototypical genetic metabolic defect in neurons and glia in vitro. The human NSCs can also replace specific deficient neuronal populations. Cryopreservable human NSCs may be propagated by both epigenetic and genetic means that are comparably safe and effective. By analogy to rodent NSCs, these observations may allow the development of NSC transplantation for a range of disorders.
849 citations
••
TL;DR: The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD, and the tolerability of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer was assessed.
849 citations
••
TL;DR: An atlas of the distribution of cholinergic cell bodies, fibers, and terminals, as well as cholinoceptive cells, in the central nervous system of the cat (excluding the cerebellum) is presented from results obtained in immunohistochemical work on choline acetyltransferase.
Abstract: An atlas of the distribution of cholinergic cell bodies, fibers, and terminals, as well as cholinoceptive cells, in the central nervous system of the cat (excluding the cerebellum) is presented from results obtained in immunohistochemical work on choline acetyltransferase. Cholinergic cell bodies are observed in more than forty areas, and cholinoceptive cells in sixty discrete areas of brain sections from the spinal cord to the olfactory bulb. The atlas is presented in seventy cross-sectional drawings of cat brain extending from the olfactory bulb to the upper cervical spinal cord.
848 citations
••
TL;DR: In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virology response.
Abstract: Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis. Methods We randomly assigned 380 patients with Child–Pugh class A cirrhosis to receive either 12 or 24 weeks of treatment with ABT-450/r–ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered according to body weight. The primary efficacy end point was a sustained virologic response 12 weeks after the end of treatment. The rate of sustained virologic response in ...
847 citations
••
TL;DR: In this article, a longitudinal study of self-enhancement in discussion groups was conducted, and the authors found that selfenhancers made positive impressions: they were seen as agreeable, well adjusted, and competent after 7 weeks, however, they were rated negatively and gave self-evaluations discrepant with peer evaluations.
Abstract: Reactions to trait self-enhancers were investigated in 2 longitudinal studies of personperception in discussion groups Groups of 4-6 participants met 7 times for 20 rain After Meetings 1 and 7, group members rated their perceptions of one another In Study 1, trait self-enhancement was indexed by measures of narcissism and self-deceptive enhancement At the first meeting, self-enhancers made positive impressions: They were seen as agreeable, well adjusted, and competent After 7 weeks, however, they were rated negatively and gave self-evaluations discrepant with peer evaluations they received In Study 2, an independent sample of observers (close acquaintances) enabled a pretest index of discrepancy self-enhancement: It predicted the same deteriorating pattern of interpersonal perceptions as the other three trait measures Nonetheless, all self-enhancement measures correlated positively with self-esteem
845 citations
Authors
Showing all 90682 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gordon H. Guyatt | 231 | 1620 | 228631 |
John C. Morris | 183 | 1441 | 168413 |
Douglas Scott | 178 | 1111 | 185229 |
John R. Yates | 177 | 1036 | 129029 |
Deborah J. Cook | 173 | 907 | 148928 |
Richard A. Gibbs | 172 | 889 | 249708 |
Evan E. Eichler | 170 | 567 | 150409 |
James F. Sallis | 169 | 825 | 144836 |
Michael Snyder | 169 | 840 | 130225 |
Jiawei Han | 168 | 1233 | 143427 |
Michael Kramer | 167 | 1713 | 127224 |
Bruce L. Miller | 163 | 1153 | 115975 |
Peter A. R. Ade | 162 | 1387 | 138051 |
Marc W. Kirschner | 162 | 457 | 102145 |
Kaj Blennow | 160 | 1845 | 116237 |